Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 328-334

  Lennard, Lynne ^a   Lilleyman, John S ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Leukaemia; Mercaptopurine; Pharmacogenetics; Thioguanine; Thioguanine nucleotides; Thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ANALYTIC METHOD; CANCER CHEMOTHERAPY; CHILD; CONFERENCE PAPER; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; INDIVIDUALIZATION; LEUKEMIA; MOLECULAR BIOLOGY; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; HUMANS; LEUKEMIA; METHYLTRANSFERASES; PATIENT COMPLIANCE; POLYMORPHISM, GENETIC; THIOGUANINE;

EID: 0029790730     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00003     Document Type: Conference Paper

References (39)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
2. Relling MV, Lin J-S, Ayers G, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-58.
3. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation, Clin Pharmacol Ther 1991;50:663-72.
4. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992; 22:1055-71.
5. Zimm S, Reaman G, Murphy RF, Poplack DG. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukaemia. Cancer Res 1986;46:1495-8.
6. Pieters R, Huismans DR, Loonen AH, et al. Hypoxanthineguanine phosphoribosyltransferase in childhood leukaemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer 1992;51:213-7.
7. Stet EH, DeAbreu RA, Janssen YPG, Bokkerink JPM, Trijbels JMF. A biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human malignant T-lymphoblastic cell line. Biochem Biophys Acta 1993; 1180:277-82.
8. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reactions of 6-mercaptopurine. Cancer Res 1974;34:738-46.
9. Klemetsdal B, Tollefsen E, Loennechen T, et al. Interethnic differences in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:24-31.
10. Lee EJD, Kalow W. Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther 1993;54:28-33.
11. McLeod HL, Lin J-S, Scott EP, Pui C-H, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharm Ther 1994;55:15-20.
12. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1982;2:148-59.
13. Lee D, Szumlanski C, Houtman J, et al. Thiopurine methyltransferase pharmacogenetics: cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995;23:398-405.
14. Szumlanski CL, Otterness DM, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
15. Krynetski EY, Schuetz JD, Galpin AJ, Pui C-H, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995;92:949-53.
16. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994; 11:2135-8.
17. Szumlanski C, Weinshilboum RM. Sulfasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine. Br J Clin Pharmacol 1995;39:456-9.
18. Glauser TA, Nelson MD, Zembower DE, Lipsky JJ, Weinshilboum RM. Diethylthiocarbamate S-methylation: evidence for catalysis by human liver thiol methyltransferase and thiopurine methyltransferase. J Pharmacol Exp Ther 1993;266: 23-32.
19. Jacqz-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E. Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994;38:1-8.
20. Lennard L, Singleton HJ. High performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr Biomed Appl 1994;661:25-33.
21. Lennard L, Singleton HJ. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
22. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine: Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med 1993;308:1005-9.
23. Lafolie P, Hayder S, Bjork O, Peterson C. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia. Eur J Clin Pharmacol 1991;40:599-601.
24. Lennard L, Lilleyman JS. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia. J Clin Oncol 1989;7;1816-23.
25. Schmeigelow K, Bruunshuus I. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukaemia, and its relation to leucopenia. Cancer Chemother Pharmacol 1990; 26:288-92
26. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188-90.
27. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
28. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-9.
29. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts VM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase deficient child with acute lymphoblastic leukaemia. J Pediatr 1991; 119:985-9.
30. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993;341:436.
31. Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995;88:155P-60P.
32. Van Loon JA, Weinshilboum RM. Human lymphocyte thiopurine methyltransferase pharmacogenetics: effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation. J Pharmacol Exp Ther 1987;242:21-6.
33. Tay BS, Lilley RM, Murray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol 1969;18:936-8.
34. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336: 225-9
35. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia. Blood 1995;85:1897-902.
36. Lennard L, Davies HA, Lilleyman JS, Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993;68:186-90.
37. Adamson PC, Poplack DG, Balis FM, The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukaemia. Leuk Res 1994;18:805-10.
38. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995;72:1004-6.
39. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.